196 related articles for article (PubMed ID: 31732528)
1. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus.
Kulik L; Laskowski J; Renner B; Woolaver R; Zhang L; Lyubchenko T; You Z; Thurman JM; Holers VM
J Immunol; 2019 Dec; 203(12):3136-3147. PubMed ID: 31732528
[TBL] [Abstract][Full Text] [Related]
2. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
[TBL] [Abstract][Full Text] [Related]
3. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
Sekine H; Kinser TT; Qiao F; Martinez E; Paulling E; Ruiz P; Gilkeson GS; Tomlinson S
Arthritis Rheum; 2011 Apr; 63(4):1076-85. PubMed ID: 21452327
[TBL] [Abstract][Full Text] [Related]
4. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.
Asokan R; Hua J; Young KA; Gould HJ; Hannan JP; Kraus DM; Szakonyi G; Grundy GJ; Chen XS; Crow MK; Holers VM
J Immunol; 2006 Jul; 177(1):383-94. PubMed ID: 16785534
[TBL] [Abstract][Full Text] [Related]
5. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
Pan Q; Xiao H; Shi L; He Y; Cai J; Wu J; Li A; Ye L; Yang C; Liu HF
Front Immunol; 2020; 11():1047. PubMed ID: 32625200
[TBL] [Abstract][Full Text] [Related]
6. Novel function of complement C3d as an autologous helper T-cell target.
Knopf PM; Rivera DS; Hai SH; McMurry J; Martin W; De Groot AS
Immunol Cell Biol; 2008; 86(3):221-5. PubMed ID: 18180801
[TBL] [Abstract][Full Text] [Related]
7. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE.
Boackle SA; Culhane KK; Brown JM; Haas M; Bao L; Quigg RJ; Holers VM
Autoimmunity; 2004 Mar; 37(2):111-23. PubMed ID: 15293881
[TBL] [Abstract][Full Text] [Related]
8. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.
Kulik L; Hewitt FB; Willis VC; Rodriguez R; Tomlinson S; Holers VM
Mol Immunol; 2015 Feb; 63(2):479-88. PubMed ID: 25457881
[TBL] [Abstract][Full Text] [Related]
9. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE).
Asokan R; Banda NK; Szakonyi G; Chen XS; Holers VM
Mol Immunol; 2013 Jan; 53(1-2):99-110. PubMed ID: 22885687
[TBL] [Abstract][Full Text] [Related]
10. Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide.
Mitsuyoshi JK; Hu Y; Test ST
Infect Immun; 2005 Nov; 73(11):7311-6. PubMed ID: 16239528
[TBL] [Abstract][Full Text] [Related]
11. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
Clemenza L; Isenman DE
J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
[TBL] [Abstract][Full Text] [Related]
12. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement.
Lee Y; Haas KM; Gor DO; Ding X; Karp DR; Greenspan NS; Poe JC; Tedder TF
J Immunol; 2005 Dec; 175(12):8011-23. PubMed ID: 16339538
[TBL] [Abstract][Full Text] [Related]
13. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
Atkinson C; Qiao F; Song H; Gilkeson GS; Tomlinson S
J Immunol; 2008 Jan; 180(2):1231-8. PubMed ID: 18178863
[TBL] [Abstract][Full Text] [Related]
14. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2.
Chen Z; Koralov SB; Kelsoe G
J Exp Med; 2000 Nov; 192(9):1339-52. PubMed ID: 11067882
[TBL] [Abstract][Full Text] [Related]
15. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice.
Takahashi K; Kozono Y; Waldschmidt TJ; Berthiaume D; Quigg RJ; Baron A; Holers VM
J Immunol; 1997 Aug; 159(3):1557-69. PubMed ID: 9233655
[TBL] [Abstract][Full Text] [Related]
16. Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells.
Thornton BP; Vetvicka V; Ross GD
Clin Exp Immunol; 1996 Jun; 104(3):531-7. PubMed ID: 9099940
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus.
Wilson JG; Ratnoff WD; Schur PH; Fearon DT
Arthritis Rheum; 1986 Jun; 29(6):739-47. PubMed ID: 2941021
[TBL] [Abstract][Full Text] [Related]
18. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists.
Kulik L; Chen K; Huber BT; Holers VM
Mol Immunol; 2011 Mar; 48(6-7):883-94. PubMed ID: 21269698
[TBL] [Abstract][Full Text] [Related]
19. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC; Myones BL; Frazier B; Holers VM
J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
[TBL] [Abstract][Full Text] [Related]
20. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.
Toapanta FR; Ross TM
Immunol Res; 2006; 36(1-3):197-210. PubMed ID: 17337780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
